(Q53325232)

13 May 2018

title

[Clinical characteristics of the neurological forms of Gaucher's disease]. (English)

1 reference

13 May 2018

1 reference

José Luis Capablo Liesa

1

1 reference

13 May 2018

Alicia Sáez de Cabezón

2

1 reference

13 May 2018

Raquel Alarcia Alejos

3

1 reference

13 May 2018

José Ramón Ara Callizo

4

1 reference

13 May 2018

language of work or name

Spanish

0 references

publication date

1 September 2011

1 reference

13 May 2018

published in

Medicina clínica

1 reference

13 May 2018

volume

137 Suppl 1

1 reference

13 May 2018

page(s)

6-11

1 reference

13 May 2018

Gaucher's disease: clinical features and natural history

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher's disease: molecular, genetic and enzymological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Neurological evaluation of patients with Gaucher disease diagnosed as type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Adult-onset neuronopathic form of Gaucher's disease: a case report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Clinical and genetic study of Japanese patients with type 3 Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Neuropathology provides clues to the pathophysiology of Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Increased incidence of Parkinson disease among relatives of patients with Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher disease and parkinsonism: a phenotypic and genotypic characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher's disease with Parkinson's disease: clinical and pathological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher disease associated with parkinsonism: four further case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Occurrence of Parkinson's syndrome in type I Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Alzheimer's disease and Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Eye movement impairment recovery in a Gaucher patient treated with miglustat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Saccade testing in the diagnosis and treatment of type 3 Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Hydrocephalus, corneal opacities, deafness, valvular heart disease, deformed toes and leptomeningeal fibrous thickening in adult siblings: a new syndrome associated with beta-glucocerebrosidase deficiency and a mosaic population of storage cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Audiometric abnormalities in children with Gaucher disease type 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Deterioration of the auditory brainstem response in children with type 3 Gaucher disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

A neurological symptom survey of patients with type I Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Review of peripheral neuropathy in plasma cell disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The risk of Parkinson's disease in type 1 Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: Case report and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher disease and the synucleinopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

alpha-Synuclein locus triplication causes Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Association of glucocerebrosidase mutations with dementia with lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Life expectancy in Gaucher disease type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Gaucher disease: resetting the clinical and scientific agenda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Increased basal glucose production in type 1 Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Divergent phenotypes in Gaucher disease implicate the role of modifiers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Acute infantile Gaucher's disease in identical twins. An account of clinical and neuropathologic observations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Central nervous system involvement in adult-onset Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Enhanced calcium release in the acute neuronopathic form of Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

A model of neuronopathic Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Enzyme therapy in Gaucher disease type 2: an autopsy case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Randomized, controlled trial of miglustat in Gaucher's disease type 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Management of neuronopathic Gaucher disease: a European consensus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2811%2970010-0

10.1016/S0025-7753(11)70010-0

7 January 2021

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018